Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

Active, not recruitingOBSERVATIONAL

Enrollment

58,387

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Diabetes Mellitus, Type 2HFpEF - Heart Failure With Preserved Ejection Fraction

Interventions

DRUG

Semaglutide

New use of semaglutide dispensing claim is used as the exposure.

DRUG

Placebo

New use of sitagliptin dispensing claim is used as the reference (active-comparator proxy for placebo).

Trial Locations (1)

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT06914102 - Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data | Biotech Hunter | Biotech Hunter